**Results**

**Figure 1. Average Monthly Dose Reduction of Epoetin Alfa and IV Iron According to Case-Mix Adjuster**

**Table 1. Population Input and Resource Utilization Input by Case-Mix**

**Table 2. Population Input and Resource Utilization Input by Case-Mix Category**

**Conclusions**

- The results of the study indicate potential cost savings for dialysis facilities through the use of FC.
- The potential mean monthly incremental cost savings would vary between $466 and $296,495 per month with FC.
- The potential monthly incremental cost savings would vary between $466 and $700 for epoetin alfa and between $174 and $220 for IV iron.
- The potential monthly reductions in the usage of ESA and IV iron would result in a decrease in the cost of dialysis care from $238 to $384 per month with FC.

**References**


**Acknowledgments**

Our sincere appreciation is extended to the team members in more than 1,800 DaVita clinics who work every day to take care of our patients and to ensure the endurance data collection on which our work is based. We thank DaVita Clinical Research (DCR), and subsidiary DaVitaCare, Inc., for their contributions. DCR is committed to advancing the knowledge and practice of kidney care.

*Contact:* Rich Mudal, MBA, R.Ph., Mudal@DaVita.com

Poster available at www.davitaclinicalresearch.com/directory.asp

**International Society for Pharmacoeconomic and Outcomes Research (ISPOR), Washington, DC, June 2-6, 2012**

Poster available at www.davitaclinicalresearch.com/directory.asp